Walden, Burgess request federal merger review of Pharmacy Benefit Managers
The Ripon Advance
U.S. Reps. Greg Walden (R-OR) and Michael Burgess (R-TX) want details about whether the mega-mergers among Pharmacy Benefit Managers (PBMs) has contributed to rising national drug prices for the more than 266 million Americans using PBM prescription drug plans…Read More.
Transparent pharmacy benefits: a path to rational drug costs
Now that states are moving to block pharmacy benefit managers from imposing “gag orders” on pharmacists, industry insiders and policymakers are sounding off louder than ever about the tendency for pharmacy benefit managers to extract value from the health system rather than add value to it…Read More.
How so-called rebates drive up the cost of prescription drugs
The Columbus Dispatch
Rebates demanded by pharmacy middleman from drug manufacturers are driving up Americans’ prescription-drug costs by billions of dollars…Read More.
States Question Costs Of Middlemen That Manage Medicaid Drug Benefits
Several states are questioning the cost of using pharmacy middlemen to manage their prescription drug programs…Read More.
Medicare Part D premiums down, CMS says, as administration aims to curtail swelling drug costs
Premiums for nursing home residents’ prescription drug plans have dipped for the second year in a row, in what the administration hopes is a sign that efforts to curb prescription costs might be taking hold…Read More.
LTC Pharmacy Group Applauds House Energy and Commerce Committee Initiative to Review PBM Mergers
SCPC Thanks U.S. Reps Greg Walden (R-OR), Gregg Harper (R-MS), Michael Burgess (R-TX)…Read More.
LTC pharmacy group rips Medicare Part D ‘oligopoly, corrupting the free market,’ offers 7 fixes
One of the leading groups representing long-term care pharmacists is urging the federal government to “act swiftly” to address “skyrocketing drug costs” that are harming the field…Read More.
New Report: Generics, Not PBMs, Key Driver of Lower Prescription Drug Spending
SCPC Offers Reforms Boosting Competition, Enhancing Transparency in Consumer Drug Marketplace…Read More.